People · Operator
Named in public records as an officer, director or promoter · active 2013–2023 · Healthtech, Hardware / Semiconductors, Other Technology, Biotechnology, Other, Computers
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Eyas Medical Imaging, Inc. | — | Healthtech | Series A | $34.5M | $73.8M | 2020 |
| Losant IoT, Inc. | — | Hardware / Semiconductors | Series A | $24.3M | $57.3M | 2017 |
| Roadtrippers Inc | — | Other Technology | Series A | $15.5M | $205.2M | 2013 |
| Airway Therapeutics, LLC | — | Biotechnology | Series A | $10.9M | $395.2M | 2018 |
| Cordata Healthcare Innovations, Inc. | — | Healthtech | Series A | $10.5M | $14.6M | 2016 |
| Lisnr, Inc. | — | Other | Seed | $4.4M | $38.7M | 2014 |
| Choremonster Inc. | — | Computers | Seed | $4.2M | $109.6M | 2013 |
| Astronomer, Inc. | — | Other Technology | Seed | $1.9M | $64.7M | 2017 |
| Chrysalis, LLC | — | Telecommunications | Pre-Seed | $100K | $2.7M | 2015 |
Michael Venerable at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Michael Venerable on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Mike Venerable | 2 | 3 |
| Jonathan Phillips | 1 | 14 |
| Mark Kvamme | 1 | 9 |
| Rachel Kern | 1 | 7 |
| Rodney Williams | 1 | 4 |
| Ryan Walker | 1 | 4 |
| Jared Stasik | 1 | 3 |
| Doug Groh | 1 | 3 |
| Justin Thompson | 1 | 3 |
| John M. Rice | 1 | 2 |
| James Fisher | 1 | 2 |
| Ted Serbinski | 1 | 2 |
| Chris Ridenour | 1 | 2 |
| Timothy Brunk | 1 | 2 |
| Edward Jackson | 1 | 2 |
| Monique Idlett | 1 | 2 |
| Chris Ostoich | 1 | 2 |
| MICHAEL RADOMSKI | 1 | 1 |
| GARY WINZENREAD | 1 | 1 |
| James Fischer | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.